Marburg virus (MARV) has been a major concern since 1967, with two major outbreaks
occurring in 1998 and 2004. Infection from MARV results in severe hemorrhagic fever …

Background Questions remain concerning the rapidity of immune responses and the
durability and safety of vaccines used to prevent Zaire Ebola virus disease. Methods We …

Viruses in the family Filoviridae, including the commonly known Ebola (EBOV) and Marburg
(MARV) viruses, can cause severe hemorrhagic fever in humans and nonhuman primates …

Summary Background The Ebola epidemics in west Africa and the Democratic Republic of
the Congo highlight an urgent need for safe and effective vaccines to prevent Ebola virus …

Background Children account for a substantial proportion of cases and deaths from Ebola
virus disease. We aimed to assess the safety and immunogenicity of a two-dose …

Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to
control the ongoing pandemic. While single-dose vaccine regimens would provide multiple …

Background Reoccurring Ebola outbreaks in West and Central Africa have led to serious
illness and death in thousands of adults and children. The objective of this study was to …

Introduction In the absence of clinical efficacy data, vaccine protective effect can be
extrapolated from animals to humans, using an immunological biomarker in humans that …

Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to
humans using an immunologic marker that correlates with protection in animals. This …

Background This study assessed the safety and immunogenicity of the Ad26. ZEBOV and
MVA-BN-Filo Ebola virus (EBOV) vaccine regimen in infants aged 4–11 months in Guinea …